Zobrazeno 1 - 10
of 129
pro vyhledávání: '"Eberhard, Kuhlisch"'
Autor:
Matthias C. Schulz, Jan Kowald, Sven Estenfelder, Roland Jung, Eberhard Kuhlisch, Uwe Eckelt, Ronald Mai, Lorenz C. Hofbauer, Christian Stroszczynski, Bernd Stadlinger
Publikováno v:
Frontiers in Physiology, Vol 8 (2017)
Osteoporosis is a systemic bone disease with an increasing prevalence in the elderly population. There is conflicting opinion about whether osteoporosis affects the alveolar bone of the jaws and whether it poses a risk to the osseointegration of dent
Externí odkaz:
https://doaj.org/article/b3cb9d99892845d9bcb4a49529f17110
Autor:
Norbert Weiss, Virginia Kamvissi, Jan Beyer-Westendorf, Thoralf Stange, Eberhard Kuhlisch, Sebastian Werth
Publikováno v:
Journal of Thrombosis and Thrombolysis. 40:26-36
Current guidelines consider outpatient treatment as an option for low-risk pulmonary embolism (PE), and risk assessment tools such as the HESTIA criteria can be used to identify PE patients who could feasibly be treated in an outpatient setting. Litt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0362a2232285685753090080c941c668
https://doi.org/10.1007/s11239-014-1141-y
https://doi.org/10.1007/s11239-014-1141-y
Autor:
Vera Gelbricht, Denise Röllig, Christina Köhler, Eberhard Kuhlisch, Sebastian Werth, Jan Beyer-Westendorf, Franziska Ebertz, Norbert Weiss, Thomas Schreier, Thoralf Stange, Luise Tittl, Ingolf Röder, Christoph Thieme, Kati Förster, Ulrike Hänsel
Publikováno v:
British Journal of Clinical Pharmacology. 78:908-917
Aim Vitamin-K antagonists (VKA) and non-vitamin-K dependent oral anticoagulants (NOAC) have been approved for anticoagulation in venous thromboembolism (VTE) and atrial fibrillation and patients previously treated with VKA are switched to NOAC therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e72c15fed3e29a163e9a490adae30aca
https://doi.org/10.1111/bcp.12391
https://doi.org/10.1111/bcp.12391
Autor:
Thoralf Stange, Christoph Thieme, Kati Förster, Franziska Ebertz, Eberhard Kuhlisch, Vera Gelbricht, Norbert Weiss, Christina Köhler, Sebastian Werth, Jan Beyer-Westendorf, Katharina Daschkow
Publikováno v:
European Heart Journal. 35:1888-1896
Aims Patients receiving novel oral anticoagulants (NOACs) frequently undergo interventional procedures. Short half-lives and rapid onset of action allow for short periods of NOAC interruption without heparin bridging. However, outcome data for this a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b79830ac752f061be328a42e09b356bd
https://doi.org/10.1093/eurheartj/eht557
https://doi.org/10.1093/eurheartj/eht557
Autor:
J. Nowotny, S. Pannach, Eberhard Kuhlisch, Kai Halbritter, Jan Beyer-Westendorf, Sebastian Schellong
Publikováno v:
Journal of Thrombosis and Haemostasis. 11:651-659
Summary Background Bleeding complications are common side effects of vitamin-K antagonist (VKA) therapy. Data on the in-hospital management and outcomes of these bleeding events are scarce and information is mostly derived from trial cohorts. Objecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc728ff56698d5205561d05872245d8c
https://doi.org/10.1111/jth.12148
https://doi.org/10.1111/jth.12148
Autor:
Albrecht Hartmann, Sebastian Werth, Jörg Lützner, Jan Beyer-Westendorf, Thoralf Stange, Lars Donath, Oliver C. Radke, Luise Tittl, Holger Knoth, Eberhard Kuhlisch, Klaus-Peter Günther, Norbert Weiss
Publikováno v:
Thrombosis and Haemostasis. 109:154-163
SummaryProspective trials have shown that rivaroxaban thromboprophylaxis is superior over low-molecular-weight heparin (LMWH) in patients undergoing hip and knee replacement surgery. However, patients treated under trial conditions are different from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d3d0cfee8131cd2271e3fd3ca137835
https://doi.org/10.1160/th12-07-0510
https://doi.org/10.1160/th12-07-0510
Publikováno v:
Vertebrate Zoology 66(2): 201-206
Variation and frequency of enamel pattern in the first lower molar (M1) in some populations of the Common Vole Microtus arvalis (Pallas, 1779). – The variation in enamel pattern (morphotyps) in the first lower molar (M1) of the Common Vole, Microtu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75ea6a78cc51e194fd2d32157b88a3c2
https://zenodo.org/record/7511893
https://zenodo.org/record/7511893
Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment
Autor:
Anna Ulmer, Meinolf Suttorp, Josephine T. Tauer, Heinz Juergen Roth, Eberhard Kuhlisch, Bernadette Anna Sophia Jaeger
Publikováno v:
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
Summary Background Imatinib is a highly effective drug in up-front treatment of chronic myeloid leukemia (CML). In children impaired longitudinal growth has been reported as side effect exerted by this drug under prolonged therapy. We therefore prosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9676cccd36c7fd45cfe85c50953c2a86
http://europepmc.org/articles/PMC3560809
http://europepmc.org/articles/PMC3560809
Autor:
H. Haberland, B. Huhn, Jürgen Koscielny, S. Petros, Eberhard Kuhlisch, Ralf Knöfler, A. Gneuss, Volker Aumann, K. Seeger, G. Syrbe, D. Franke, Robert Klamroth, A. Hofmann, Karim Kentouche, J. T. Tauer
Publikováno v:
Hämostaseologie. 32:271-275
SummaryIntroduction: Desmopressin (DDAVP) testing (DT) in patients (pts) with haemophilia A (HA) and carriers (CHA) is up to now not standardized. This prompted us to evaluate results of DT carried out between 1996 and 2011 in centres of the Competen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f4e9a46e294ae401cf85562d3e0ce54
https://doi.org/10.5482/hamo-12-06-0012
https://doi.org/10.5482/hamo-12-06-0012
Autor:
Martin W. Laass, Michael Neumeyer, Manfred Stolte, Michael Vieth, Marco Berning, Christian Zekorn, Ahmed Madisch, Holger Knoth, Stephan Miehlke, Wulf Schneider-Brachert, Norbert Lehn, Claus Jebens, Susanne Krasz, Eberhard Kuhlisch, Andrea Morgner
Publikováno v:
Helicobacter. 16:420-426
Background: Triple therapy with a proton pump inhibitor, moxifloxacin, and amoxicillin has been proven effective in first-line treatment of Helicobacter pylori infection. Aim: To explore 1, the value of triple therapy with esomeprazole, moxifloxacin,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c741d7cdfdda5730ddb6b6223f3de8db
https://doi.org/10.1111/j.1523-5378.2011.00867.x
https://doi.org/10.1111/j.1523-5378.2011.00867.x